Rgenta Therapeutics is developing a pipeline of oral small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. The company’s proprietary platform mines large genomics datasets to identify targetable RNA processing events and design small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Led by CEO Simon Xi, Rgenta is advancing multiple lead programs discovered via this platform. The company plans to use its new capital to speed development of lead programs, enhance target discovery capabilities, and extend platform functionality. The financing is intended to support advancement of a pipeline of RNA-targeting programs across a range of disease indications. No operating metrics were disclosed in the article. Rgenta Therapeutics is a US-based therapeutics company. The company announced an $18 million seed extension round. The extension was backed by Lilly Asia Ventures, which the article describes as China-headquartered. The article does not provide details on Rgenta’s products, pipeline, revenue, users, valuation, or use of proceeds. No other investors, prior rounds, or founding year were mentioned in the coverage. Further operational or financial details were not disclosed. Based in Cambridge, Mass., Rgenta Therapeutics is developing oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Its proprietary platform mines large genomics datasets to identify targetable RNA processing events and design small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. The company says its discovery engine can rapidly screen for drug-like small molecules to regulate protein production or alter protein function against historically undruggable targets. Rgenta plans to advance its lead RNA-targeting programs into preclinical studies and expand its portfolio to pursue high-value RNA targets across therapeutic areas. The company launched with a $20 million seed investment co-led by Boehringer Ingelheim Venture Fund and Matrix Partners China, with Kaitai Capital and Legend Star Fund participating. Rgenta has assembled a team of small-molecule drug developers and a scientific advisory board including Dr. Zhiping Weng, Dr. Phillip Zamore, Dr. Charles DeLisi, and Dr. Friedrich Metzger.

Total raised

$90M

Funding rounds

3

Latest round

Series A

Latest activity

Nov 2022